Overcome Screening Barriers in CRC

The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve biliary tract cancer.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Developing a strong working relationships and understanding the physical and emotional demands of the oncology specialty are some ways nurses can address burnout, an expert said.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

The fast track status from the FDA is supported by findings from a phase 1 trial in glioblastoma, which demonstrated the overall survival benefit from DOC1021.

The overall survival rate in patients with advanced biliary tract cancer treated with durvalumab plus chemotherapy was nearly double the rate of those treated with chemotherapy alone.